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ABSTRACT
We describe a case of ventricular fibrillation occurring in a patient with multi-vessel coronary spasm after the initiation of an oral beta-
blocker. A 56-year-old man began to experience chest discomfort and his computed tomography revealed intermediate coronary stenoses. 
He was administered medications including an oral beta-blocker but suddenly collapsed while walking 4 days later. An automated external 
defibrillator detected ventricular fibrillation and delivered successful electrical cardioversion. An acetylcholine provocation test after 
stabilization of the status revealed triple-vessel coronary spasm. Beta-blockers may provoke exacerbation of coronary spasm and result in 
lethal arrhythmia.
LEARNING POINTS
• Beta-blockers which have a vasoconstrictive effect may occasionally provoke exacerbation of coronary spasm.
• Coronary spasm should be considered as a cause of lethal ventricular arrhythmia or cardiac arrest.
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INTRODUCTION
Beta-blockers have a vasoconstrictive effect and may provoke exacerbation of coronary spasm[1]. It is known that coronary spasm can cause 
serious arrhythmias and consequently sudden cardiac death[2]. We herein describe a case of ventricular fibrillation occurring in a patient 
with multi-vessel coronary spasm 4 days after the initiation of an oral beta-blocker.
CASE REPORT
A 56-year-old man with a history of dyslipidaemia began to experience chest discomfort on effort and at rest. He presented to a local hospital 
where coronary computed tomography revealed intermediate stenoses in the mid portion of the left anterior descending artery (LAD) and 
the first diagonal branch. The patient was prescribed medications including low-dose aspirin, a statin and a beta-blocker (atenolol 25 mg 
once daily), but his symptoms worsened. 
Four days later he took his medications and went shopping on foot. At 10 am, he suddenly collapsed while walking. Cardiac massage was 
immediately performed by bystanders and after 5 min of resuscitation effort, an automated external defibrillator (AED) was attached. It 
detected ventricular fibrillation and delivered a successful electrical cardioversion (Fig. 1A). The AED electrocardiogram (ECG) record just 
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after successful cardioversion showed ST-segment elevation (Fig. 1B), which disappeared promptly (Fig. 1C). After the return of spontaneous 
circulation, the patient was brought to the emergency department of our hospital. 
Figure 1: The electrocardiogram record of the automated external defibrillator
At presentation to the emergency department, his ECG and chest x-ray showed almost normal findings. Laboratory analysis revealed 
normal values for complete blood cell counts, electrolytes and cardiac biomarkers. We performed emergency coronary angiography (CAG) 
(Fig. 2A–C), which showed intermediate stenoses in the mid portion of the LAD and the first diagonal branch (Fig. 2B, black arrow) and 
normal coronary flow in each coronary artery. Based on the cardiac catheterization findings, we ruled out acute coronary syndrome due to 
coronary plaque rupture as the cause of the ventricular fibrillation. After CAG, we performed intensive care including targeted temperature 
management and intravenous injection of nicorandil for the prevention of coronary spasm. Following treatment, the patient regained 
a stable cardiopulmonary status and had no serious ventricular arrhythmias. His neurological status gradually improved and he did not 
experience any residual neurological deficits.
Eight days after the episode of ventricular fibrillation, we performed an acetylcholine provocation test for coronary spasm after a 48 h 
drug holiday from vasodilators. After baseline coronary angiography (Fig. 2D–F), intracoronary injection of 20 μg of acetylcholine into the 
right coronary artery (RCA) and left coronary artery (LCA) provoked coronary spasm of the RCA (Fig. 2G, black arrow head), LAD (Fig. 2H, 
white arrow head) and left circumflex coronary artery (LCX) (Fig.2I, black arrow). Next, we measured fractional flow reserve, which was 
0.85 for the distal LAD, and 0.92 for the first diagonal branch. The patient was diagnosed as having multi-vessel coronary spasm, and the 
intermediate stenotic lesions of the LAD and the first diagonal branch were not considered to be significant. We prescribed an oral calcium 
antagonist (nifedipine sustained released tablet, 20 mg twice daily). Fifteen days after the ventricular fibrillation event, we performed a 
cardiac electrophysiological study while the patient was on an oral calcium antagonist. Programmed ventricular stimulation did not induce 
reproducible ventricular arrhythmia even with triple extra-stimuli from the right ventricular apex and outflow tract. We therefore attributed 
the patient’s cardiopulmonary arrest to coronary spasm, and continue to prescribe an oral calcium antagonist. Since the initiation of calcium 
antagonist, the patient has been free from any angina symptoms and ventricular arrhythmias.
DISCUSSION
Beta-blockers reduce heart rate and contractility, resulting in relief of myocardial ischaemia. However, blockade of the vasodilatory β
2
-
adrenergic effect even with β
1
-selective agents[3] and relative enhancement of the vasoconstrictive α1-adrenergic effect[1] can result in 
exacerbation of coronary spasm and provoke lethal arrhythmia. In this case, the patient had experienced ventricular fibrillation 4 days after 
the initiation of an oral β
1
-selective adrenergic blocker, and was ultimately diagnosed as having multi-vessel coronary spasm. The fact that 
multi-vessel spasm was provoked by intracoronary injection of low-dose acetylcholine indicates that this patient’s baseline coronary artery 
tone may be high. To our knowledge, there are few cases of the initiation of oral beta-blocker therapy resulting in ventricular fibrillation in 
patients with coronary spastic angina. 
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Coronary spasm can cause critical ischaemic heart disease. In particular, multi-vessel spasm is often complicated by lethal ventricular 
arrhythmias[4], similar to our case. A previous study reported that reperfusion after coronary spasm, rather than coronary spasm itself, 
correlated with the onset of ventricular arrhythmia in some cases[4]. Those patients may not be diagnosed as having coronary spasm 
following emergency coronary angiography just after resuscitation. Physicians should perform a spasm provocation test after the patient 
has stabilized and emergency coronary angiography had not revealed any likely cardiac lesions, because coronary spasm was detected in 
11% of patients who survived cardiac arrest without structural heart disease[5]. Coronary spasm is a more common cause of lethal ventricular 
arrhythmia or cardiac arrest than one might expect. 
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Figure 2: Emergency coronary angiography (A-C) and elective acetylcholine provocation test (D-F: baseline coronary angiography, G-I: acetylcholine provocation test)
